Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00555451 · ClinicalTrials.gov registry record · Phase 1
Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects
A Phase 1 study of Insulin Resistance, sponsored by Harbor Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
- 2
- Study locations
NCT00555451: Completed Phase 1 study of Insulin Resistance, sponsored by Harbor Therapeutics.
NCT00555451 is a Phase 1 study of Insulin Resistance that has completed, run by Harbor Therapeutics. The registered enrollment target is 66 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00555451, a Phase 1 study of Insulin Resistance, has completed, sponsored by Harbor Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objectives of this study are to evaluate the safety, tolerance and pharmacokinetics of HE3286 when administered daily for 28 days to obese adult subjects and to assess potential activity of HE3286 to decrease insulin resistance. An open-label cohort of 6 patients with type II diabetes mellitus will be treated at 10 mg (5 mg BID).
Conditions Studied
Interventions
- DRUG HE3286
Study Locations (2)
Louisiana
- - Baton Rouge
Texas
- dgd Research, Inc. - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
What the finished NCT00555451 record still lists
NCT00555451 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Insulin Resistance appearing as the primary indexed condition, and to 1 intervention - of which HE3286 is the first listed.
NCT00555451 reports a single indexed study location in Louisiana, Texas.
Frequently Asked Questions
What is clinical trial NCT00555451 about?
NCT00555451 is a clinical study titled "Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects". The objectives of this study are to evaluate the safety, tolerance and pharmacokinetics of HE3286 when administered daily for 28 days to obese adult subjects and to assess potential activity of HE3286 to decrease insulin resistance. An open-label cohort of 6 patients with type II diabetes mellitus w...
What is the current status of trial NCT00555451?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2007-10. Estimated completion is 2009-09.
What conditions does trial NCT00555451 study?
This clinical trial studies the following conditions: Insulin Resistance.
What interventions are being tested in trial NCT00555451?
The interventions under investigation include: HE3286 (DRUG).
Who is sponsoring clinical trial NCT00555451?
This trial is sponsored by Harbor Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00555451 being conducted?
This trial has 2 study locations across Louisiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Resistance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00555451's enrollment target sits among peer trials
66 42nd of 120 higher than 78 of 120 other Insulin Resistance trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insulin Resistance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
-
Graded Insulin Suppression Test P&F
RECRUITING · Phase 1
-
Diazoxide Suppression Test P&F Study
RECRUITING · Phase 1
-
Mitigating the Pro-inflammatory Phenotype of Obesity
RECRUITING · Phase 1
-
Human Models of Selective Insulin Resistance: Alpelisib, Part I
RECRUITING · Phase 1
-
Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia